Impact BioMedical to Improve Testing Efficiency of Pan-Coronavirus...

Pharma Tech Outlook: Pharma Tech Magazine

Impact BioMedical to Improve Testing Efficiency of Pan-Coronavirus Vaccine

By Pharma Tech Outlook | Wednesday, October 14, 2020

Impact BioMedical will improve the efficiency of testing a pan-coronavirus vaccine with the help of a wholly-owned subsidiary, Innate Immune.

FREMONT, CA: Document Security Systems, Inc. is a multinational company that focuses on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. The company has announced that its wholly-owned subsidiary Impact BioMedical, Inc. (Impact BioMedical) has formed a new wholly-owned subsidiary, Innate Immune, Inc. (Innate Immune) with the aim to improve the efficiency of testing a pan-coronavirus vaccine, which is a particular type of vaccine designed to protect against multiple coronaviruses.

According to Daryl Thompson, Impact BioLife's Director of Scientific Initiatives and Founder of Advanced Research Company GRDG Sciences, LLC ("GRDG"), "Highly pathogenic human coronaviruses are continuously emerging and remain a major threat to human health.Our pan-coronavirus vaccine is designed to allow us to not only protect against COVID-19, which is likely here to stay, but also allow for us to quickly respond to any outbreaks of a virus of this type in the future."

Coronavirus belongs to a large family of viruses and is common all over the world. Presently seven known human coronaviruses can make people sick. The typical human coronaviruses consist of 229E, NL63, OC43, and HKU1. These viruses cause mild to moderate upper-respiratory tract illnesses. On the other hand, MERS-CoV, SARS-CoV, and now SARS-CoV2 can create more dangerous respiratory illness.

"COVID-19 has already cost more than one million lives and continues to disrupt the $133 trillion global economy," commented Jason Grady, COO of DSS. "A successful pan-coronavirus vaccine could save countless lives while lessening or even preventing the types of disruptions we have seen this year that have impacted nearly everyone on the planet."

Innate Immune's orally delivered pan-coronavirus vaccine has a well-established safety profile. It is designed to be used for global distribution, ease of manufacturing, and a high degree of stability. Innate Immune has even assembled a globally recognized team of virologists to complete the research necessary and bring the vaccine to market.

"The need for a solution to COVID-19 and potential future human coronaviruses is clear. We believe this vaccine can provide that solution while remaining economically affordable, ensuring availability across the globe," stated Chan Heng Fai, Chairman of DSS.

Weekly Brief

Read Also